{"name":"Nanexa AB","slug":"nanexa-ab","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"NEX-18a injection","genericName":"NEX-18a injection","slug":"nex-18a-injection","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"NEX-18a injection","genericName":"NEX-18a injection","slug":"nex-18a-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihAJBVV95cUxORTNKQ0swa00xVGl2NFFFLTdwQzFxWnBiX0UyZnlmYk42eEY4cXA4SzAzQkFXZkxxLXVleS1hQ2JWd3dsMGgyZldNcDhiU3lkcV8xaFdZaTM0ZnM2c1huOGpKQW41ZVNaNHRBbUo5dUdzVDFLTFR0U0tjd29hT1RIdnNXbDV6SUpMLThPdVo3YmtqeGZZcWNRa2VUX1VGM2hDOTRzVDVBNE1GaDdzcU8zZmZLSlZyb3VtbUhLWkhUVW9YTXVVeFhDeWtjWV8tS3BncHJTR3o3SHBMVzZmNkVmb3J3WGxyU3dxamxCRmNFT1dHZXhnakJqVTJ5YnZaRmktc2J4WQ?oc=5","date":"2026-03-19","type":"regulatory","source":"Finansavisen","summary":"Nanexa Demonstrates Feasibility of Quarterly Semaglutide Dosing with PharmaShell® - Finansavisen","headline":"Nanexa Demonstrates Feasibility of Quarterly Semaglutide Dosing with PharmaShell®","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxNN1BGZElSb0dncFJIZWdQaGdKQV8xcWUtd2dUNjlZdkRZSml4MVJ6MEEtUG5aTjBNRVN5SkVBMWxEVXZpcTVJMmVEblZEd2pjX3FpSUhKQzhLZnl3LUdQWl9yTmM0Y0hPdEFDWWI2Y3pJQkZFY1BTRU1CaEVrLWo2bmlqRV8tU1FUN29DdldyalVHMDJKU2dnejctOXliZ3BhRzhCR1NDRUE5aGRkRTZLTm5OLThxZTVMb1d0eHFKaVZmS0RDMjA0SjhGN1A1NHV4SGhVQzFEV0pWTlhjMk9WdjJEa1N4UG1DYjQxUmxnYktPcmZ1NDB5NjlR?oc=5","date":"2026-02-24","type":"pipeline","source":"Finansavisen","summary":"Nomination Committee for the 2026 Annual General Meeting in Nanexa AB (publ) - Finansavisen","headline":"Nomination Committee for the 2026 Annual General Meeting in Nanexa AB (publ)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAJBVV95cUxQeTlweFBqOTBuUjVpaVZPZW1kT1VMMHd0QzdITnVrUUc5cW12ZV9na081clIweW1SdUdIX0tCVXM1SC1tZFBCN2U2dlVCVHZtOFZMNGljT1VWRF8zckpXbkFXdWFmZzJFaXBzMjZocHJHTXduRHpzdXlURmRHd29WRV95dllJdmF2WUhDaEpIcnNGVTNkM1FIRXNTTHRRWng1d2o5M0hvckREMEpiTm1ZRUxxVUEya3h4c0VhQmpLOXAzTWdsQlN2UFB3Ml9JNU1rLXBjVG1UWTZjQ3hVdFFycWpFems2TUt2MnE0YVBZY0xxMkk4M3FHNl9qd09xbDRzRE5CV2RGUWVhTjNFTDNPbXg2anR6dDhYMHo2czNmQW1VRW9FWnB2REtQbm5OTlhLcUNleGFQVXFzdHZLRk1jRjRPb1E?oc=5","date":"2026-01-27","type":"regulatory","source":"Finansavisen","summary":"Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation - Finansavisen","headline":"Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOb255QWR6SXNGTG5LcDk1bmhSdmtMT1FHOVVlVzNZXzcyNm9DYjhoRHhtNzlSTE5KanhObFdYTkFNTi01cUg4VDZxM0RrX2FaMF9nZGg0TzNURF9nSXlzeHJNVWFRR2JMa2t2QUhkcW1rczdMQ1A1UFBCWW5GajlTXzVGdml4dThZcUZHM0pFZGNIU2c3UlZUQnUwLXNycUlDLTRYZUVocWdrRkoxUDN4NlA2MlhHVVB4eThv?oc=5","date":"2025-12-12","type":"deal","source":"European Pharmaceutical Review","summary":"Nanexa collaboration to enhance Moderna’s mRNA drug delivery - European Pharmaceutical Review","headline":"Nanexa collaboration to enhance Moderna’s mRNA drug delivery","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipwJBVV95cUxNMHNsMUdUaHd5MDhUR0RtUTBhaGdQdDNvY3Y4U0FsLWgyQ3ZWS2k2djRkZGw0ZmhISzZ5ZEpBb0drcTVUMEVWQnRUMXNSZnNkNV94bC0td1UzTzBZcDFnellKU3FtSmFKMDM4ZlQxQVlsQWNaeVBiSk1nSWxneWZCaHlqSmVrcUJuRk04MjkxVkwxdVduNlZvVE9NU3U0T1k1cWlVUmN5Ny1kaFJJT0hUMDFucGJRckJySmNnb3RNWHJRUGdNdWhzdnNXTkl2NnpSblV2Wk5MdUQ5VmNJZ0FRRWpFbThMQUVxNGs3cGJnX013NC1DWVhRNTllbW1oRjItazZtb3FEM0ZCNF9wMHQ3aFJKTnQ3MmJFdkhLbHhMMzlvVFhuSlR3?oc=5","date":"2025-12-10","type":"deal","source":"Finansavisen","summary":"Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products - Finansavisen","headline":"Nanexa and Moderna enter into license and option agreement for the development of PharmaShell®-based products","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAJBVV95cUxObFdEVmRIaFRmNk16TG5YNHhqQXdlUnNlQnhiZ1pvQ1F0M0lUbDlKa3VlY3VSYlFWNWdNNmJJbG1WVy1aYmU3NFU2bFdJNGI4WWJtZ2JJeVl3V1l5QWdtQlQwUWFYRTJOY2xiTEhnazkzaXlEdGFBcDd2RGhoangyd0hhRmNNMnViWTdwY1ZabVJyanB6SEp1dE40bFFoMGhtT195dWdRZ0hMTks2b2hheG9sUHhUMnhUWnZ3ZVk5Q3ZnZ0VkNFVyNVNfWXQ4UUVxcXZqOGhERjFmSkJuaUFvMngwUm8wVHNqamdHVVhQVGRFbFY0a2tnVzZxd0ExdDVM?oc=5","date":"2025-10-16","type":"pipeline","source":"Finansavisen","summary":"Nanexa named as finalist in Fierce Innovation Awards Life Sciences Edition 2025 - Finansavisen","headline":"Nanexa named as finalist in Fierce Innovation Awards Life Sciences Edition 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxPd3hzR3NGTUxRNkdQamltOWlkYy03eWRGS0RtTDEtbFZma1NSMFVqWkRFM0pFZ1dwV2lUOWRhODAzbFBqcGJWT0lvOUdPNnJEWlJlUlp0ZTR2MVpuUUlzNXBDT2JVVUFwMFh3R0xuRWl6SS05bHN6Nm5ubm5Vc2ZJeHU0b1hBN2NLTWVlNHE3QzVLUkVBa3VFb3lPenhmZVAtSTVOWnNNSUg1d2o3enRQUmVUY0tsV2FISGh2U2o3Mko0aTc5YU8yZXNzVHBEQUhvSWJURzBUMGtwWnA3SGZHdQ?oc=5","date":"2025-10-01","type":"deal","source":"Finansavisen","summary":"Nanexa AB changes Certified Adviser to Tapper Partners AB - Finansavisen","headline":"Nanexa AB changes Certified Adviser to Tapper Partners AB","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4gFBVV95cUxQOFVDd2VDMGJOY0IyX1diTXIwZE1yOWhfUTBYOWdaVXh2MHFjYW5xOEJOOUFDTVNFR1J3Q0tIX3duMVlERkZCcjMwejhjcS05eUJCajFJUnZBWENCQmZ5cFhOTFJUVmg4XzFFZnI3My1sVU9CZGZyTE5uaEEwQlIyTUh4RGlqal9mR0Rrc1p1dlFpYm9sRzg0M29mak1iUW1XaWxveUx3QlpZY3lDYkFmc25zR0dRT3ZWLVpSS0ZJaG9lNlM1R05iVmlVUHdMSThDaXNPeEE1VmJyT3d6SWpxNmZ3?oc=5","date":"2025-09-30","type":"pipeline","source":"Finansavisen","summary":"Nanexa publishes interim report for January-September 2025 - Finansavisen","headline":"Nanexa publishes interim report for January-September 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-wFBVV95cUxNZmdZZUJPYlFzWlhneXJ3c2poZnFjbVlaRy1DM2h3ZjQxb0NmYWI1Ym5JVUFFVlZPTjN4YnNqOUg3UVU4eXU1UmRPR3RMaTZxTFBKcGY3UGVJRjNJTS1kRXg3YlNxd2U4MXBjcVotOVhwZEhfN2VIWW9HblBxenk2QmlBdDhXanB1dTZWVmR6NkxDSjRkdlNOQkI3YXhWWW51UHE0S09BWnVDOXpZblVOQmlqRll3V2d0NjlMZTRxQUlhSk53OXktZnBVRk1HOHUwWk4xWW1ZeWxUa0tIOUkyLTREYUpWUFk5VWxLZXlkdldERE1BdHNDa0NsVQ?oc=5","date":"2025-09-22","type":"regulatory","source":"Finansavisen","summary":"Nanexa receives Japanese patent approval for specific PharmaShell structure - Finansavisen","headline":"Nanexa receives Japanese patent approval for specific PharmaShell structure","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMisAJBVV95cUxPdWk5SHFGVGZDV3NSRGQ4NmlVemNCbXY1d3JlSUk4Z19mdkg1NkNOV0h0Zi1Vb3g0REsxRExUaHlscE9YSmZfTEJYWDdYQTEzTWc1bC1NYi1rX2s5UzZ0WENXaGlQTmcxN2VFVmdJblE4dGtUTWZGdjR0RlFpVnFuNEpBYV9xaUdCbmZqbGJJcHFPRWl1UkJOWHdIR2o5WXhZTWU4dEVKYzRrMjRCU3lmM0UxeGUxal9mUlZodzhKZkNSbWJLUUdoOUtLUHJHcnZQOHNOUnlYdS1XLU5LU0M3ZHlKQ1hCbFpqVzdpcEx3aGxGdUJ3bmVBUU0zbHM4THR5R1Awb003b1k1TW92VUxPU1hVNjBBNDB2X2kxQzBqTV9DcmFvaG15NV9fRkg5QjhV?oc=5","date":"2025-08-28","type":"trial","source":"Finansavisen","summary":"Emergers: Equity Research | NANEXA AB: Positive clinical data balanced by strategic uncertainty about NEX-22 roadmap - Finansavisen","headline":"Emergers: Equity Research | NANEXA AB: Positive clinical data balanced by strategic uncertainty about NEX-22 roadmap","sentiment":"positive"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}